Clinical trials: Hormone Therapy
Breast Cancer
Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer
- Trial name
- NCT00721409
- Testing
- PD 0332991, letrozole
- Where
- 104 sites in United States, Canada and 10 more
- Volunteers
- 177 people
- Sponsor
- Pfizer
Metastatic Prostate Cancer
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
This is a randomized, double blind, multi-institutional phase II therapeutic study of Indoximod or placebo after the completion of standard of care sipuleucel-T (Provenge®) in men with asymptomatic or minimally symptomatic…
- Trial name
- NCT01560923
- Testing
- Indoximod, Sipuleucel-T
- Where
- 4 sites in United States
- Volunteers
- 47 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen.
- Trial name
- TEXT (NCT00066703)
- Testing
- exemestane, tamoxifen, triptorelin
- Where
- 228 sites in United States, Australia and 15 more
- Volunteers
- 2,672 people
- Sponsor
- ETOP IBCSG Partners Foundation
Hormone Deficiency, Aging
Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly
The purpose of the study is to evaluate the effect of a naturally occurring hormone, called Growth Hormone Releasing Hormone (GHRH) on the muscle, bone, and fat tissues of the body.
- Trial name
- NCT01410799
- Testing
- Growth Hormone Releasing Hormone (GHRH )
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Post Menopausal Women With Early Breast Cancer
Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)
Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire. Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane).
- Trial name
- FAST (NCT01050634)
- Testing
- Aromasin (exemestane)
- Volunteers
- 980 people
- Sponsor
- Pfizer
Premenstrual Dysphoric Disorder
Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)
The purpose of this study is to compare a low dose oral contraceptive (OC) given continuously (every day for three months) with the same low dose oral contraceptive given in an interrupted regimen (one week of inactive placebo…
- Trial name
- PMDD (NCT00927095)
- Testing
- Continuous OC (EE/DROS), Intermittent OC (EE/DROS)
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of North Carolina, Chapel Hill
Epilepsy
Progesterone vs Placebo Therapy for Women With Epilepsy
The purpose of this investigation was to determine if cyclic adjunctive progesterone supplement is superior to placebo in the treatment of intractable seizures in women with and without catamenial epilepsy.
- Trial name
- NCT00029536
- Testing
- Progesterone Lozenges
- Where
- 15 sites in United States, Canada
- Volunteers
- 294 people
- Sponsor
- Beth Israel Deaconess Medical Center
Anorexia Nervosa, Eating Disorder
Hormonal Factors in the Treatment of Anorexia Nervosa
The investigators are investigating whether a hormone that is naturally produced by the human body, called testosterone, can help improve weight, disordered eating, depression, and anxiety.
- Conditions
- Anorexia Nervosa, Eating Disorder, Anxiety, Depression
- Trial name
- NCT01121211
- Testing
- Testosterone
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Massachusetts General Hospital
Hypoparathyroidism
A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)
This study is a long-term, open-label study using NPSP558 for the treatment of adult patients with Hypoparathyroidism.
- Trial name
- NCT01297309
- Testing
- NPSP558
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Shire
Transgenderism
Transgender Estradiol Affirming Therapy
The purpose of this open label, pilot, randomized clinical trial is to evaluate the effectiveness, safety and tolerability of estrogen use in transgender female and the degree of testosterone suppression achieved in this…
- Trial name
- TREAT (NCT05010707)
- Testing
- Transdermal patch, Pro-thrombotic markers, Metabolic markers
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included.
- Conditions
- Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
- Trial name
- NCT03305016
- Testing
- TransCon hGH
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 146 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Vaginal Atrophy
A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study to explore the safety of 0.005% estriol vaginal gel in women with early stage breast cancer in…
- Trial name
- BLISSAFE (NCT02413008)
- Testing
- estriol
- Where
- 6 sites in Spain, Sweden
- Volunteers
- 61 people
- Sponsor
- ITF Research Pharma, S.L.U.
Foetal Growth Problem, Small for Gestational Age
Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
This study is conducted in Japan. The aim of this trial is to assess the efficacy and safety of somatropin in children born small for gestational age (SGA) in Japan.
- Trial name
- NCT00184717
- Testing
- somatropin
- Where
- Japan
- Volunteers
- 98 people
- Sponsor
- Novo Nordisk A/S
Breast Cancer, Stage II Breast Cancer
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
This phase II trial studies how well exemestane before surgery works in treating postmenopausal patients with newly diagnosed estrogen receptor positive stage II-III breast cancer.
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT01831076
- Testing
- Exemestane, Exemestane and tamoxifen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Colorado, Denver
Osteoporosis, Prostate Cancer
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
RATIONALE: Zoledronate may prevent bone loss in patients with prostate cancer undergoing radiation therapy and hormone therapy. It is not yet known whether zoledronate is more effective than calcium and vitamin D alone in…
- Trial name
- NCT00329797
- Testing
- Calcium, Zoledronic acid, radiation therapy
- Where
- 88 sites in United States, Canada
- Volunteers
- 109 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
The study is being done to find out whether combining two FDA approved drugs along with radiation therapy for the treatment of high risk localized prostate cancer is safe and well tolerated.
- Trial name
- NCT02064582
- Testing
- Enzalutamide, Leuprolide acetate, radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Obesity
Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment
This is a two-phase study. Phase 1 will evaluate obesity-related behavioral and biological characteristics as potential predictors of response to behavioral treatment (BT) for weight loss.
- Trial name
- NCT03779048
- Testing
- Behavioral Treatment, Phentermine 15 MG
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- University of Pennsylvania
Breast Cancer
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib.
- Trial name
- NCT05966584
- Testing
- Benralizumab, fulvestrant or AIs) and PI3K inhibition (alpelisib)
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer, Breast Carcinoma
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
This is a randomized trial for patients with metastatic hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have progressed on an aromatase inhibitor plus a CDK4/6 inhibitor…
- Trial name
- MAINTAIN (NCT02632045)
- Testing
- LEE-011, Fulvestrant
- Where
- 13 sites in United States
- Volunteers
- 169 people
- Sponsor
- Melissa K Accordino
Breast Cancer
Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer
RATIONALE: Clodronate may be effective in preventing the spread of cancer to the bones and other parts of the body. It is not yet known whether clodronate is more effective alone or combined with chemotherapy and /or hormonal…
- Trial name
- NCT00009945
- Testing
- clodronate
- Where
- 17 sites in United States
- Volunteers
- 3,323 people
- Sponsor
- NSABP Foundation Inc